Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Leiden University Medical Center)

异基因骨髓源间充质干细胞（Leiden University）

Report date: 2024/11/30 20:00:04

Base Information

Drug NameAllogeneic bone marrow-derived mesenchymal stromal cell therapy (Leiden University Medical Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsGraft RejectionFistulaDiabetic Foot +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsItalyDenmark +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLeiden University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeiden University Medical CenterMario Negri Institute For Pharmacological Research
Active IndicationsN/A
Inactive IndicationsGraft RejectionFistulaDiabetic Foot +[5] 

Other Information

ATC CodeN/A
Related LinksN/A